Board of Trustees of The Leland Stanford Junior University Purchases Shares of 623,751 CeriBell (NASDAQ:CBLL)

Board of Trustees of The Leland Stanford Junior University purchased a new position in CeriBell (NASDAQ:CBLL - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 623,751 shares of the company's stock, valued at approximately $16,143,000. CeriBell comprises approximately 1.4% of Board of Trustees of The Leland Stanford Junior University's holdings, making the stock its 7th biggest position. Board of Trustees of The Leland Stanford Junior University owned about 1.74% of CeriBell as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. FMR LLC bought a new position in CeriBell in the 4th quarter valued at $128,120,000. Vanguard Group Inc. bought a new stake in CeriBell during the 4th quarter valued at about $18,015,000. Franklin Resources Inc. purchased a new stake in CeriBell in the 4th quarter valued at about $12,460,000. Massachusetts Financial Services Co. MA purchased a new position in shares of CeriBell during the fourth quarter worth approximately $10,750,000. Finally, Federated Hermes Inc. bought a new stake in shares of CeriBell during the fourth quarter valued at approximately $9,634,000.

Wall Street Analysts Forecast Growth

Several research analysts have commented on CBLL shares. Canaccord Genuity Group restated a "buy" rating and set a $33.00 price objective on shares of CeriBell in a report on Wednesday, February 26th. LADENBURG THALM/SH SH began coverage on shares of CeriBell in a report on Friday, April 4th. They set a "buy" rating and a $32.00 target price on the stock. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, CeriBell currently has a consensus rating of "Buy" and an average target price of $32.50.

CeriBell Stock Performance

Shares of CBLL stock traded up $0.36 during mid-day trading on Friday, hitting $14.85. 621,578 shares of the stock traded hands, compared to its average volume of 268,776. CeriBell has a 52-week low of $10.01 and a 52-week high of $32.75. The stock's fifty day moving average price is $20.45.

CeriBell (NASDAQ:CBLL - Get Free Report) last announced its earnings results on Tuesday, February 25th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.08). The business had revenue of $18.53 million for the quarter, compared to the consensus estimate of $17.55 million. As a group, equities analysts predict that CeriBell will post -2.46 earnings per share for the current fiscal year.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.